Small Intestinal Lymphoma
Associated Genetic Biomarkers
NCI Definition: A non-Hodgkin or Hodgkin lymphoma that arises from the small intestine. 
There are 2 clinical trials for small intestinal lymphoma, of which 2 are open and 0 are completed or closed. Of the trials that contain small intestinal lymphoma as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open).
CD7 and MYC are the most frequent gene inclusion criteria for small intestinal lymphoma clinical trials .
Anti-cd7 car t-cells, autologous hematopoietic stem cell transplantation, and carmustine are the most common interventions in small intestinal lymphoma clinical trials.
Significant Genes in Small Intestinal Lymphoma
MYC is an inclusion eligibility criterion in 1 clinical trial for small intestinal lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and small intestinal lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.